+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Schizophrenia Therapeutics Market - Global Forecast to 2030- Product Image
Schizophrenia Therapeutics Market - Global Forecast to 2030- Product Image
Sale

Schizophrenia Therapeutics Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012570
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Schizophrenia Therapeutics Market grew from USD 5.89 billion in 2024 to USD 6.21 billion in 2025. It is expected to continue growing at a CAGR of 5.49%, reaching USD 8.12 billion by 2030.

Schizophrenia represents one of the most intricate and challenging psychiatric disorders of our time, characterized by its chronic course, heterogeneity of symptoms, and profound impact on patients, families, and healthcare systems. Historically, treatment paradigms centered on symptom suppression through pharmacological interventions, yet significant gaps in efficacy, tolerability, and patient adherence persist. Over recent years, a confluence of scientific breakthroughs, regulatory evolution, and shifting care models has begun to reshape the therapeutic landscape. Novel mechanisms of action are emerging alongside digital health solutions and patient-centric therapeutic approaches, offering new hope for improved long-term outcomes. As decision-makers grapple with escalating development costs, pricing pressures, and evolving reimbursement frameworks, a nuanced understanding of market dynamics becomes essential. This executive summary synthesizes key trends, regulatory influences, segmentation patterns, regional variances, and competitive strategies that collectively define the current state of schizophrenia therapeutics. Through targeted insights and strategic recommendations, stakeholders will gain the clarity needed to navigate complexity, capitalize on innovation, and ultimately deliver more effective, accessible care for those affected by this debilitating condition.

Transformative Shifts Reshaping Schizophrenia Care

Over the past decade, schizophrenia care has undergone transformative shifts driven by technological innovation, evolving regulatory priorities, and a growing emphasis on personalized medicine. Precision psychiatry initiatives leverage genetic and biomarker data to refine patient stratification, while real-world evidence platforms integrate digital monitoring tools to evaluate treatment adherence and long-term outcomes. Concurrently, policy makers and payers are advancing value-based reimbursement models that reward meaningful clinical improvements and cost containment. In parallel, the convergence of pharmacological and non-pharmacological modalities underscores a holistic approach: cognitive-behavioral therapy, family interventions, and novel device-assisted neuromodulation techniques are increasingly integrated alongside established antipsychotics and mood stabilizers. Telepsychiatry expansions have improved access in rural and underserved regions, catalyzing hybrid care pathways that blend in-person and virtual engagement. These dynamic forces are forging a new paradigm in which therapeutic success hinges on agility, evidence-driven collaboration, and a relentless focus on improving patient quality of life.

Cumulative Impact of 2025 United States Tariffs on Schizophrenia Treatments

Anticipated tariff adjustments in 2025 present a critical inflection point for the supply chain and pricing strategies within the United States schizophrenia therapeutics market. Heightened duties on imported active pharmaceutical ingredients and finished products introduce cost pressures that may reverberate across manufacturers, distributors, and payers. In response, industry leaders are reevaluating sourcing models, expanding domestic manufacturing capabilities, and exploring contract manufacturing partnerships to mitigate margin erosion. Pricing negotiations with payers will increasingly hinge on value demonstration, compelling sponsors to strengthen real-world evidence of clinical and economic benefits. Meanwhile, patient access programs and co-payment assistance initiatives will play a pivotal role in sustaining treatment adherence amid potential out-of-pocket increases. By proactively addressing tariff-induced cost escalations through strategic supply-chain diversification and rigorous value communication, stakeholders can safeguard continuity of care and preserve market momentum despite an evolving trade environment.

Key Segmentation Insights Driving Therapeutic Strategies

A granular understanding of market segments reveals nuanced opportunities and strategic imperatives across therapy modalities, mechanisms of action, delivery formats, care settings, and patient populations. Based on Type, the market divides into non-pharmacological therapies-such as cognitive-behavioral therapy, electroconvulsive therapy, and family therapy-and pharmacological therapies encompassing both injectable medications and oral formulations. When viewed by Therapeutic Class, antipsychotics-segmented into first-generation and second-generation agents-coexist with mood stabilizers and selective serotonin reuptake inhibitors. Mechanism-of-action analysis highlights dopamine receptor antagonists alongside emerging glutamate modulators and serotonin-dopamine activity modulators. Considering Formulation Type, the industry offers inserts and patches, liquid solutions, and solid tablets, each catering to distinct adherence and pharmacokinetic profiles. End users span home-based care settings, hospitals, specialized mental health clinics, and research institutes, while patient settings bifurcate into inpatient and outpatient care. Finally, demographic segmentation distinguishes adult, geriatric, and pediatric cohorts, each presenting unique therapeutic needs and regulatory considerations. By synthesizing these lenses, leaders can prioritize R&D investments, tailor commercial strategies, and optimize patient outreach for maximum clinical and financial impact.

Critical Regional Dynamics in Schizophrenia Therapeutics

Regional dynamics exert significant influence on market evolution, with distinctive drivers and barriers shaping growth trajectories. In the Americas, robust R&D infrastructure, established reimbursement pathways, and high per-capita healthcare spending underpin sustained leadership in both novel and generics segments. Regulatory agility and incentive programs further accelerate early-stage innovation. Meanwhile, Europe, Middle East & Africa exhibits a heterogeneous landscape: Western Europe’s harmonized frameworks facilitate cross-border market entry, while emerging economies within the Middle East and Africa strive to strengthen mental health infrastructure and expand patient access. Reimbursement volatility and pricing scrutiny in key European markets necessitate differentiated value narratives. Turning to Asia-Pacific, rapid expansion of healthcare infrastructure, rising patient awareness, and growing public-private partnerships drive adoption of both pioneering therapies and cost-effective generics. Local manufacturing capabilities and regulatory reforms increasingly attract global sponsors, positioning the region as a critical growth frontier for schizophrenia therapeutics.

Leading Industry Players and Their Strategic Positioning

Competitive positioning across leading organizations underscores a dynamic interplay of innovation, lifecycle management, and strategic alliances. AbbVie Inc. and AstraZeneca plc pursue novel mechanisms and extended-release formulations, while Acadia Pharmaceuticals Inc. and BioXcel Therapeutics, Inc. leverage cutting-edge AI platforms to accelerate candidate selection. Alkermes Plc and Lundbeck A/S focus on next-generation antipsychotics with enhanced tolerability profiles, and Bristol Myers Squibb Company combines in-house R&D with targeted acquisitions to diversify therapeutic portfolios. Eli Lilly and Company and Novartis AG champion digital adherence tools alongside standard-of-care antipsychotics to bolster patient engagement. Generic specialists such as Cipla Limited, Dr. Reddy’s Laboratories Ltd., and Sun Pharmaceutical Industries Limited drive cost-effective access, while specialty innovators like Vanda Pharmaceuticals Inc. and Reviva Pharmaceuticals Holdings, Inc. explore repurposing opportunities and novel delivery systems. Collaborative networks among Johnson & Johnson Services, Inc., Merck & Co., Inc., and Otsuka Holdings Co., Ltd. further exemplify the power of cross-sector partnerships in advancing clinical development and amplifying global reach.

Actionable Recommendations for Sustained Competitive Advantage

To capitalize on emerging opportunities and fortify market standing, stakeholders should pursue several priority actions. First, integrate digital health platforms and telepsychiatry into standard care pathways to enhance adherence tracking, remote monitoring, and patient engagement. Second, diversify supply chains by forging domestic manufacturing alliances and leveraging regional hubs to mitigate tariff-related risks and ensure uninterrupted API availability. Third, invest in real-world evidence generation to substantiate value claims, support negotiations with payers, and align with evolving value-based reimbursement paradigms. Fourth, accelerate development of long-acting formulations, device-assisted therapies, and novel mechanisms that address unmet clinical needs and reduce relapse rates. Fifth, tailor commercialization models to demographic and regional nuances, applying differentiated pricing and patient support initiatives for adult, geriatric, and pediatric populations. By executing these concerted measures, industry leaders can drive sustainable growth, elevate standards of care, and reinforce competitive differentiation.

Conclusion: Charting the Path Forward in Schizophrenia Therapeutics

The schizophrenia therapeutics market stands at the nexus of innovation, regulatory evolution, and shifting care paradigms. Our comprehensive analysis highlights how transformative shifts in precision psychiatry, digital integration, and non-pharmacological modalities are converging to redefine treatment pathways. Tariff-induced cost pressures in the United States accentuate the need for strategic supply-chain resilience and value-focused communication. Detailed segmentation insights reveal high-potential submarkets-ranging from long-acting injectable antipsychotics to family therapy programs-while regional dynamics underscore the importance of tailored market entry and reimbursement strategies. A diverse competitive landscape, featuring both large-cap pharmaceutical leaders and agile biotech innovators, further emphasizes the imperative of strategic partnerships and lifecycle extension. By aligning on these core insights and pursuing targeted recommendations, stakeholders can confidently navigate emerging challenges, capitalize on growth frontiers, and ultimately improve outcomes for individuals living with schizophrenia.

Market Segmentation & Coverage

This research report categorizes the Schizophrenia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Non-Pharmacological Therapies
    • Cognitive-Behavioral Therapy (CBT)
    • Electroconvulsive Therapy (ECT)
    • Family Therapy
  • Pharmacological Therapies
    • Injectable Medications
    • Oral Medications
  • Antipsychotics
    • First-Generation Antipsychotics
    • Second-Generation Antipsychotics
  • Mood Stabilizers
  • Selective Serotonin Reuptake Inhibitors
  • Dopamine Receptor Antagonists
  • Glutamate Modulators
  • Serotonin Dopamine Activity Modulators
  • Inserts and Patches
  • Liquid Solutions
  • Solid Tablets
  • Homecare Settings
  • Hospitals
  • Mental Health Clinics
  • Research Institutes
  • Inpatient Care
  • Outpatient Care
  • Adult Patients
  • Geriatric Patients
  • Pediatric Patients

This research report categorizes the Schizophrenia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • Massachusetts
      • New York
      • North Carolina
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Schizophrenia Therapeutics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Alkermes Plc
  • Amneal Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • BioXcel Therapeutics, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Delpor, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Gedeon Richter Plc
  • GlaxoSmithKline plc.
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lundbeck A/S
  • Lupin Limited
  • Luye Pharma Group Ltd
  • Lyndra Therapeutics Inc
  • Meiji Holdings Co., Ltd.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Reviva Pharmaceuticals Holdings, Inc.
  • Sanofi S.A
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Vanda Pharmaceuticals Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Schizophrenia Therapeutics Market, by Type
8.1. Introduction
8.2. Non-Pharmacological Therapies
8.2.1. Cognitive-Behavioral Therapy (CBT)
8.2.2. Electroconvulsive Therapy (ECT)
8.2.3. Family Therapy
8.3. Pharmacological Therapies
8.3.1. Injectable Medications
8.3.2. Oral Medications
9. Schizophrenia Therapeutics Market, by Therapeutic Class
9.1. Introduction
9.2. Antipsychotics
9.2.1. First-Generation Antipsychotics
9.2.2. Second-Generation Antipsychotics
9.3. Mood Stabilizers
9.4. Selective Serotonin Reuptake Inhibitors
10. Schizophrenia Therapeutics Market, by Mechanism of Action
10.1. Introduction
10.2. Dopamine Receptor Antagonists
10.3. Glutamate Modulators
10.4. Serotonin Dopamine Activity Modulators
11. Schizophrenia Therapeutics Market, by Formulation Type
11.1. Introduction
11.2. Inserts and Patches
11.3. Liquid Solutions
11.4. Solid Tablets
12. Schizophrenia Therapeutics Market, by End Users
12.1. Introduction
12.2. Homecare Settings
12.3. Hospitals
12.4. Mental Health Clinics
12.5. Research Institutes
13. Schizophrenia Therapeutics Market, by Patient Settings
13.1. Introduction
13.2. Inpatient Care
13.3. Outpatient Care
14. Schizophrenia Therapeutics Market, by Patient Demographics
14.1. Introduction
14.2. Adult Patients
14.3. Geriatric Patients
14.4. Pediatric Patients
15. Americas Schizophrenia Therapeutics Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Schizophrenia Therapeutics Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Schizophrenia Therapeutics Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. AbbVie Inc.
18.3.2. Acadia Pharmaceuticals Inc.
18.3.3. Alkermes Plc
18.3.4. Amneal Pharmaceuticals, LLC
18.3.5. Astellas Pharma Inc.
18.3.6. AstraZeneca plc
18.3.7. BioXcel Therapeutics, Inc.
18.3.8. Boehringer Ingelheim International GmbH
18.3.9. Bristol Myers Squibb Company
18.3.10. Cipla Limited
18.3.11. Delpor, Inc.
18.3.12. Dr. Reddy’s Laboratories Ltd.
18.3.13. Eli Lilly and Company
18.3.14. Gedeon Richter Plc
18.3.15. GlaxoSmithKline plc.
18.3.16. Glenmark Pharmaceuticals Limited
18.3.17. Johnson & Johnson Services, Inc.
18.3.18. Lundbeck A/S
18.3.19. Lupin Limited
18.3.20. Luye Pharma Group Ltd
18.3.21. Lyndra Therapeutics Inc
18.3.22. Meiji Holdings Co., Ltd.
18.3.23. Merck & Co., Inc.
18.3.24. Neurocrine Biosciences, Inc.
18.3.25. Novartis AG
18.3.26. Otsuka Holdings Co., Ltd.
18.3.27. Pfizer Inc.
18.3.28. Reviva Pharmaceuticals Holdings, Inc.
18.3.29. Sanofi S.A
18.3.30. Sumitomo Pharma Co., Ltd.
18.3.31. Sun Pharmaceutical Industries Limited
18.3.32. Takeda Pharmaceutical Company Limited
18.3.33. Teva Pharmaceutical Industries Ltd.
18.3.34. Torrent Pharmaceuticals Ltd.
18.3.35. Vanda Pharmaceuticals Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. SCHIZOPHRENIA THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. SCHIZOPHRENIA THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. SCHIZOPHRENIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SCHIZOPHRENIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 74. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 75. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 76. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 77. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 78. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 79. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 80. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 81. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 82. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 83. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 86. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 87. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 88. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 90. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 91. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 116. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 118. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 119. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 120. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 121. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 126. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 128. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 129. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 130. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 131. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 132. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 133. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 134. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 135. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 136. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 138. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 139. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 140. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 141. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 142. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 143. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 144. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 145. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 146. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 148. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 149. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 150. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 151. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 156. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 158. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 159. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 160. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 161. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 162. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 163. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 164. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 165. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 166. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 168. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 169. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 170. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 171. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 176. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 178. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 179. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 180. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 181. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 186. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 187. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 188. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 189. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 190. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 191. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 196. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 198. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 199. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 200. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 206. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 207. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 208. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 209. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 210. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 211. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 216. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 217. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 218. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 219. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 220. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 221. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 222. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 223. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 224. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 225. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 226. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 228. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 229. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 230. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 231. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 247. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 248. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 249. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 250. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 251. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 252. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 253. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 254. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 255. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 256. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 257. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 258. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 259. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 260. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 261. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 262. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 263. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 264. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 265. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 266. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 267. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 268. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 269. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 270. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 271. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 272. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 273. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 274. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 275. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 276. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 277. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 278. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 279. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 280. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 281. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 282. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 283. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 284. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 285. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 286. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 287. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 288. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 289. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 290. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 291. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 292. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 293. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 294. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 295. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 296. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 302. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 307. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 308. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-P

Companies Mentioned

  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Alkermes Plc
  • Amneal Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • BioXcel Therapeutics, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Delpor, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Gedeon Richter Plc
  • GlaxoSmithKline plc.
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lundbeck A/S
  • Lupin Limited
  • Luye Pharma Group Ltd
  • Lyndra Therapeutics Inc
  • Meiji Holdings Co., Ltd.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Reviva Pharmaceuticals Holdings, Inc.
  • Sanofi S.A
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Vanda Pharmaceuticals Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Schizophrenia Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Schizophrenia Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Schizophrenia Therapeutics - Global Strategic Business Report - Product Image

Schizophrenia Therapeutics - Global Strategic Business Report

  • Report
  • 197 Pages
  • Global
From
Schizophrenia Drugs Market Size, Share and Trends Analysis Report by Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, Others), Treatment, Distribution Channels, and Region 2024-2030 - Product Image

Schizophrenia Drugs Market Size, Share and Trends Analysis Report by Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, Others), Treatment, Distribution Channels, and Region 2024-2030

  • Report
  • 100 Pages
  • Global
From
Antipsychotic Drugs - Global Strategic Business Report - Product Image

Antipsychotic Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Schizophrenia: Seven-Market Drug Forecast and Market Analysis - Update - Product Image

Schizophrenia: Seven-Market Drug Forecast and Market Analysis - Update

  • Report
  • 144 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.